Opus Genetics (IRD) EBITDA (2010 - 2026)
Opus Genetics (IRD) posted quarterly EBITDA of -$14.4 million for Q1 2026, down 44.67% year-over-year from -$26.0 million in Q1 2025, and down 25.42% quarter-over-quarter from -$11.5 million in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) EBITDA (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported EBITDA for 17 consecutive years, with -$14.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 44.67% year-over-year to -$14.4 million; the TTM figure through Mar 2026 stood at -$43.0 million (up 33.07% YoY), while the FY2025 annual figure was -$38.6 million, up 37.82% from the prior year.
- EBITDA slipped to -$14.4 million in Q1 2026 per IRD's latest filing, from -$11.5 million in the prior quarter.
- Across five years, EBITDA topped out at $34.2 million in Q4 2022 and bottomed at -$38.0 million in Q4 2024.
- Historically, EBITDA has averaged -$6.3 million across 5 years, with a median of -$7.7 million in 2024.
- Annual changes were most pronounced in 2022 — EBITDA soared 656.26% — and 2024, when it sank 600.48%.
- Opus Genetics' EBITDA stood at $34.2 million in 2022, then sank by 115.87% to -$5.4 million in 2023, then tumbled by 600.48% to -$38.0 million in 2024, then jumped by 69.88% to -$11.5 million in 2025, then retreated by 25.42% to -$14.4 million in 2026.
- Business Quant data shows IRD's EBITDA at -$14.4 million in Q1 2026, -$11.5 million in Q4 2025, and -$8.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | -16.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.48 Mn |
| Mar 31, 2026 | -14.36 Mn |
| Dec 31, 2025 | -11.45 Mn |
| Sep 30, 2025 | -8.31 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Mar 31, 2025 | -9.93 Mn |
| Dec 31, 2024 | -38.03 Mn |
| Sep 30, 2024 | -8.01 Mn |
| Jun 30, 2024 | -8.33 Mn |
| Mar 31, 2024 | -7.71 Mn |
| Dec 31, 2023 | -5.43 Mn |
| Sep 30, 2023 | 6.39 Mn |
| Jun 30, 2023 | -5.39 Mn |
| Mar 31, 2023 | -6.13 Mn |
| Dec 31, 2022 | 34.21 Mn |
| Sep 30, 2022 | -4.54 Mn |
| Jun 30, 2022 | -4.94 Mn |
| Mar 31, 2022 | -6.51 Mn |
| Dec 31, 2021 | -6.15 Mn |
| Sep 30, 2021 | -4.23 Mn |